Where data
becomes
discovery.
discovery.
Partnering with pharma, biotech, and investors to bring earlier clarity and reduce development risk.
Collaborating with Pharma through
discovery.
discovery.
Partnering with pharma, biotech, and investors to bring earlier clarity and reduce development risk.
Where data
becomes
discovery.
discovery.
Partnering with pharma, biotech, and investors to bring earlier clarity and reduce development risk.
Explority AI Use Cases
who we work with
who we work with
who we work with
Collaborating with pharma.
We work at the intersection of AI and pharmaceutical industry. The goal is simple but ambitious: earlier clarity, fewer dead ends, and faster progress in bringing rare disease therapies to patients.
Big Pharma
Biotech
BioVCs
Explority AI helps big pharma teams reduce late-stage failures by forecasting approval success early, focusing R&D and partnering resources on therapies most likely to reach patients.
Unlock data-driven clarity across thousands of therapies, allowing your team to focus resources on programs most likely to reach patients.
We enable biotech investors to source and diligenciate opportunities earlier, identify standout science, and deploy capital with quantified approval likelihoods.
Big Pharma
Biotech
BioVCs
Explority AI helps big pharma teams reduce late-stage failures by forecasting approval success early, focusing R&D and partnering resources on therapies most likely to reach patients.
Unlock data-driven clarity across thousands of therapies, allowing your team to focus resources on programs most likely to reach patients.
We enable biotech investors to source and diligenciate opportunities earlier, identify standout science, and deploy capital with quantified approval likelihoods.
Big Pharma
Biotech
BioVCs
Explority AI helps big pharma teams reduce late-stage failures by forecasting approval success early, focusing R&D and partnering resources on therapies most likely to reach patients.
Unlock data-driven clarity across thousands of therapies, allowing your team to focus resources on programs most likely to reach patients.
We enable biotech investors to source and diligenciate opportunities earlier, identify standout science, and deploy capital with quantified approval likelihoods.
Frequently Asked Questions
What problem does Explority AI solve?
Drug discovery projects in their early stages are extremely risky – only 1 in 40 preclinical candidates ever reaches approval. Yet, 76% of funding in the pharmaceutical industry is allocated to these early-stage programs in an attempt to drive innovation, but it is not allocated as efficiently or as timely as it could be.
What is the “likelihood of approval”?
Likelihood of approval is a quantified forecast of whether an early-stage therapy will ultimately reach regulatory approval. Explority AI generates this likelihood by analyzing published scientific literature —providing an evidence-based signal years before traditional clinical or regulatory indicators emerge.
How does Explority AI predict success so early in development?
Explority AI uses large language models trained on all published drug discovery research and real-world regulatory outcomes. We first structure research across targets, mechanisms, and compounds, then train AI classifiers to learn patterns that historically led to orphan designation and approval. This allows us to evaluate new research ideas and forecast their success long before clinical data is available.
How do pharma, biotech, and investors use Explority AI in practice?
Pharma and biotech teams use Explority AI to prioritize R&D portfolios, reduce late-stage failures, and guide partnering decisions. Investors use it to source and diligenciate opportunities earlier, identify standout science, and deploy capital with quantified risk. In all cases, the platform provides objective clarity to focus resources on therapies most likely to reach patients.
What problem does Explority AI solve?
Drug discovery projects in their early stages are extremely risky – only 1 in 40 preclinical candidates ever reaches approval. Yet, 76% of funding in the pharmaceutical industry is allocated to these early-stage programs in an attempt to drive innovation, but it is not allocated as efficiently or as timely as it could be.
What is the “likelihood of approval”?
Likelihood of approval is a quantified forecast of whether an early-stage therapy will ultimately reach regulatory approval. Explority AI generates this likelihood by analyzing published scientific literature —providing an evidence-based signal years before traditional clinical or regulatory indicators emerge.
How does Explority AI predict success so early in development?
Explority AI uses large language models trained on all published drug discovery research and real-world regulatory outcomes. We first structure research across targets, mechanisms, and compounds, then train AI classifiers to learn patterns that historically led to orphan designation and approval. This allows us to evaluate new research ideas and forecast their success long before clinical data is available.
How do pharma, biotech, and investors use Explority AI in practice?
Pharma and biotech teams use Explority AI to prioritize R&D portfolios, reduce late-stage failures, and guide partnering decisions. Investors use it to source and diligenciate opportunities earlier, identify standout science, and deploy capital with quantified risk. In all cases, the platform provides objective clarity to focus resources on therapies most likely to reach patients.
What problem does Explority AI solve?
Drug discovery projects in their early stages are extremely risky – only 1 in 40 preclinical candidates ever reaches approval. Yet, 76% of funding in the pharmaceutical industry is allocated to these early-stage programs in an attempt to drive innovation, but it is not allocated as efficiently or as timely as it could be.
What is the “likelihood of approval”?
Likelihood of approval is a quantified forecast of whether an early-stage therapy will ultimately reach regulatory approval. Explority AI generates this likelihood by analyzing published scientific literature —providing an evidence-based signal years before traditional clinical or regulatory indicators emerge.
How does Explority AI predict success so early in development?
Explority AI uses large language models trained on all published drug discovery research and real-world regulatory outcomes. We first structure research across targets, mechanisms, and compounds, then train AI classifiers to learn patterns that historically led to orphan designation and approval. This allows us to evaluate new research ideas and forecast their success long before clinical data is available.
How do pharma, biotech, and investors use Explority AI in practice?
Pharma and biotech teams use Explority AI to prioritize R&D portfolios, reduce late-stage failures, and guide partnering decisions. Investors use it to source and diligenciate opportunities earlier, identify standout science, and deploy capital with quantified risk. In all cases, the platform provides objective clarity to focus resources on therapies most likely to reach patients.